We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
KindLink are a social network for donors and charities so donors are able to make a donation to their favourite charity and help them help other people. Donors are able to see the impact of the donations they are making by following the progress of the charity and updates for the project donated to. KindLink establishes a direct connection between donor and beneficiary to create a close and community-like feel.
days to go: Expired investment: £25,045
epaysecure is a secure payment system, which offers comprehensive payment and benefit options, and allows all the services the consumer demands to be offered in one card and e-account. The prepaid business purchasing in European markets is estimated to be $700 million. The company operates in an e-banking and financial services marketing sector that helps clients by identifying new markets and bringing in new ideas to develop them through reloadable products and e-Wallet platform. The funds will be used for staffing, set up costs, other overheads including property marketing and general office costs.

Pitch Rated

73%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £168,340
Genuine Impact is the next generation financial terminal made exclusively to empower DIY investors by providing experts with automation tools, portfolio enhancer, unbiased data and insights. Genuine Impact is more cost-effective in comparison with traditional financial terminals, and it makes financial research effortless and efficient. Currently, the company's beta app has 500+ users from more than 27 countries. With the proceeds, the fund raised will be used for new product development, enhancement of existing product and for marketing and branding.
days to go: Expired investment: £500,920
Celo is an app-based insurance provider designed to provide cheaper quotes, faster claims, and a pleasant user experience. We plan to offer insurance cover for motor vehicles, travel, health, and more. Like Monzo and Starling who are disrupting banking, Celo plans to disrupt the insurance industry.

Pitch Rated

39%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £142,840
Doc2UK is a specialist UK medical recruitment and candidate support platform. Based in London, the platform places qualified doctors in the National Health Scheme (NHS) roles around the United Kingdom. The British Medical Association (2018) reported that patient care is at risk due to a critical shortage of doctors across multiple medical disciplines. At present, the UK only has 24 medical schools to fill this gap, whilst India, in comparison, has 468 medical schools, with 68,000 doctors graduating each year. Moreover, uncertainty about the status of EU nationals after Brexit, changes to immigration policies, and the impact of changing language testing requirements for international nurses have made this crisis worse. This situation necessitates recruiting doctors from overseas an important endeavour. This is where Doc2UK aims to become a key player and ensure that lack of medical personnel doesn't disrupt any medical services. The company is seeking an investment of up to £300,000 which will be used to develop the platform with more features, expand the team, marketing and sales.

Pitch Rated

66%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
Luas Diagnostics (LD) aims to develop and market easy-to-use, rapid and accurate diagnostics tests with the aim of deploying these tests in remote settings away from centralised testing laboratories. The company has signed an exclusive distribution agreement with Chembio Diagnostics Systems (CDS) in the USA to market its Covid-19 antibody and antigen tests in the UK and Ireland. It has also signed a Memorandum of Understanding (MoU) with the University of Birmingham to develop saliva-based, rapid Covid-19 tests. LD is also working on coming up with a therapeutic drug monitoring system based on the same technology used worldwide to test people with diabetes for glucose levels in the blood. The company is developing the system so that it can be used at home, in pharmacies or GP surgery. The first product will test for Theophylline which is used to treat Chronic Obstructive Pulmonary Disease (COPD). LD will use the investment to grow its business across different verticals.

Pitch Rated

81%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £326,190
Klymat's SaaS business model transforms vehicle fleet management for organizations and fulfills employees' transportation requirements. Through a centralized online platform offered via monthly subscriptions, Klymat empowers businesses to monitor their entire vehicle fleet and employee journeys, regardless of transportation mode. The software computes total business mobility costs and carbon emissions, providing a simpler, more visible, flexible, cost-effective, sustainable, and eco-friendly approach to corporate travel.
days to go: Expired investment: Withheld
Aerobit is a smart inhaler, a tool for tracking medication use that records each time inhalers are taken and comes in a variety of cool toy designs. Built in sensors can even tell if the inhaler has been shaken correctly. 
days to go: Expired investment: £116,960
Polydone is a project management platform to help tech companies plan and manage tasks, projects and people. The platform is easy to use and uses automation, artificial intelligence and machine learning to help businesses plan timelines and obtain accurate estimates - helping businesses to avoid human error by 90%. Polydone currently caters for tech companies of up to 50 people but will be expanding to other sectors and larger teams in the future. 
days to go: Expired investment: £128,106
BiVictriX Therapeutics is a pharmaceutical company that are developing ADC's (Antibody Drug Conjugates) in the field of Oncology. They have invented a strategy that improves ADC selectivity towards cancer cells.
days to go: Expired investment: £451,506
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph